Incidence of treatment-emergent adverse events was similar between the two groups , with the most common events being respiratory disorders ( 31 [ 62 % ] of 50 patients given placebo vs 32 [ 63 % ] of 51 given benralizumab ) and infections ( 28 [ 56 % ] vs 27 [ 53 % ] ) .